Progress report on new antiepileptic drugs: A summary of the Eigth Eilat Conference (EILAT VIII)

The Eigth Eilat Conference on New Antiepileptic Drugs (AEDs)-EILAT VII, took place in Sitges, Barcelona from the 10th to 14th September, 2006. Basic scientists, clinical pharmacologists and neurologists from 24 countries attended the conference, whose main themes included a focus on status epilepticus (epidemiology, current and future treatments), evidence-based treatment guidelines and the potential of neurostimulation in refractory epilepsy. Consistent with previous formats of this conference, the central part of the conference was devoted to a review of AEDs in development, as well as updates on marketed AEDs introduced since 1989. This article summarizes the information presented on drugs in development, including brivaracetam, eslicarbazepine acetate (BIA-2-093), fluorofelbamate, ganaxolone, huperzine, lacosamide, retigabine, rufinamide, seletracetam, stiripentol, talampanel, valrocemide, JZP-4, NS1209, PID and RWJ-333369. Updates on felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine and new extended release oxcarbazepine formulations, pregabalin, tiagabine, topiramate, vigabatrin, zonisamide and new extended release valproic acid formulations, and the antiepileptic vagal stimulator device are also presented.

[1]  P. White,et al.  Gabapentin: An Alternative to the Cyclooxygenase-2 Inhibitors for Perioperative Pain Management , 2006, Anesthesia and analgesia.

[2]  J. Sackellares,et al.  Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). , 1993, The New England journal of medicine.

[3]  G. Ferron,et al.  Multiple‐Dose, Linear, Dose‐Proportional Pharmacokinetics of Retigabine in Healthy Volunteers , 2002, Journal of clinical pharmacology.

[4]  A. Mamelak,et al.  Vagus nerve stimulation therapy: 2-year prospective open-label study of 40 subjects with refractory epilepsy and low IQ who are living in long-term care facilities , 2005, Epilepsy & Behavior.

[5]  B. Jensen,et al.  The anticonvulsant retigabine attenuates nociceptive behaviours in rat models of persistent and neuropathic pain. , 2003, European journal of pharmacology.

[6]  A. Schulze-Bonhage,et al.  Determination of Gabapentin-lactam in Serum of Patients under Gabapentin Therapy , 2004, Arzneimittelforschung.

[7]  G. Bennett,et al.  Characterization of the anticonvulsant profile and enantioselective pharmacokinetics of the chiral valproylamide propylisopropyl acetamide in rodents , 2003, British journal of pharmacology.

[8]  W. Turski,et al.  AMPA and GABA(B) receptor antagonists and their interaction in rats with a genetic form of absence epilepsy. , 2001, European journal of pharmacology.

[9]  T. Tomson,et al.  Pharmacokinetics of Gabapentin during Delivery, in the Neonatal Period, and Lactation: Does a Fetal Accumulation Occur during Pregnancy? , 2005, Epilepsia.

[10]  V. Caprio,et al.  A radical mediated approach to the core structure of huperzine A , 2006 .

[11]  A. Falcão,et al.  Effect of Food on the Pharmacokinetic Profile of Eslicarbazepine Acetate (BIA 2-093) , 2005, Drugs in R&D.

[12]  T. Pugsley,et al.  Stimulus-dependent modulation of [(3)H]norepinephrine release from rat neocortical slices by gabapentin and pregabalin. , 2000, The Journal of pharmacology and experimental therapeutics.

[13]  M. Rogawski,et al.  Neurosteroids: Endogenous Modulators of Seizure Susceptibility , 2004 .

[14]  R H Levy,et al.  Influence of stiripentol on cytochrome P450‐mediated metabolic pathways in humans: In vitro and in vivo comparison and calculation of in vivo inhibition constants , 1997, Clinical pharmacology and therapeutics.

[15]  D. Lewis,et al.  Losing Neurons: Selective Vulnerability and Mesial Temporal Sclerosis , 2005, Epilepsia.

[16]  T. Branchek,et al.  Tiagabine, SK&F 89976-A, CI-966, and NNC-711 are selective for the cloned GABA transporter GAT-1. , 1994, European journal of pharmacology.

[17]  C. Chiron,et al.  IN VITRO AND IN VIVO INHIBITORY EFFECT OF STIRIPENTOL ON CLOBAZAM METABOLISM , 2006, Drug Metabolism and Disposition.

[18]  M. Bialer,et al.  New CNS-active drugs which are second-generation valproic acid , 2003 .

[19]  I. Rosén,et al.  Beneficial effects on sleep of vagus nerve stimulation in children with therapy resistant epilepsy. , 2005, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[20]  A. Turan,et al.  Effect of oral gabapentin on postoperative epidural analgesia. , 2006, British journal of anaesthesia.

[21]  S. Weinstein,et al.  Adjunctive therapy with oxcarbazepine in children with partial seizures , 2000, Neurology.

[22]  R. Sachdeo,et al.  Felbamate monotherapy: Controlled trial in patients with partial onset seizures , 1992, Annals of neurology.

[23]  Y. Ben-Ari,et al.  Stiripentol, a Putative Antiepileptic Drug, Enhances the Duration of Opening of GABAA‐Receptor Channels , 2006, Epilepsia.

[24]  J. French,et al.  Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures , 2003, Neurology.

[25]  Jin Zhou,et al.  Huperzine A attenuates apoptosis and mitochondria‐dependent caspase‐3 in rat cortical neurons , 2002, FEBS letters.

[26]  M. Bialer,et al.  New CNS-active drugs which are second-generation valproic acid: can they lead to the development of a magic bullet? , 2003, Current opinion in neurology.

[27]  E. Ben-Menachem,et al.  Efficacy and Safety of Oral Lacosamide as Adjunctive Therapy in Adults with Partial‐Onset Seizures , 2007, Epilepsia.

[28]  W. Blume,et al.  Divalproex extended-release versus the original divalproex tablet: results of a randomized, crossover study of well-controlled epileptic patients with primary generalized seizures , 2002, Epilepsy Research.

[29]  E. Zrenner,et al.  Visual field constriction and electrophysiological changes associated with vigabatrin , 2002, Documenta Ophthalmologica.

[30]  R. Shrivastava,et al.  A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, Multicenter Study of Pregabalin in Patients With Generalized Anxiety Disorder , 2003, Journal of clinical psychopharmacology.

[31]  J. Calabrese,et al.  Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. , 2006, The American journal of psychiatry.

[32]  M. Gillard,et al.  Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein. , 2006, European journal of pharmacology.

[33]  B. Bourgeois,et al.  Ganaxolone for treating intractable infantile spasms: a multicenter, open-label, add-on trial , 2000, Epilepsy Research.

[34]  B. MacVicar,et al.  Topiramate Inhibits the Initiation of Plateau Potentials in CA1 Neurons by Depressing R‐type Calcium Channels , 2005, Epilepsia.

[35]  C. Rundfeldt,et al.  D-23129: a potent anticonvulsant in the amygdala kindling model of complex partial seizures. , 1996, European journal of pharmacology.

[36]  P. Goadsby,et al.  Topiramate inhibits cortical spreading depression in rat and cat: impact in migraine aura , 2005, Neuroreport.

[37]  E. Perucca,et al.  Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V) , 2001, Epilepsy Research.

[38]  C. Grunwald,et al.  Metabolism of retigabine (D-23129), a novel anticonvulsant. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[39]  A. Berardelli,et al.  Topiramate and cortical excitability in humans: a study with repetitive transcranial magnetic stimulation , 2006, Experimental Brain Research.

[40]  M. Rogawski,et al.  Role of AMPA and GluR5 kainate receptors in the development and expression of amygdala kindling in the mouse , 2001, Neuropharmacology.

[41]  W. Garnett,et al.  Extended Release Formulations of Anticonvulsant Medications , 2000 .

[42]  J. Dahl,et al.  Effects of gabapentin on postoperative morphine consumption and pain after abdominal hysterectomy: A randomized, double‐blind trial , 2004, Acta anaesthesiologica Scandinavica.

[43]  M. Holmes,et al.  Effect of vagus nerve stimulation on adults with pharmacoresistant generalized epilepsy syndromes , 2004, Seizure.

[44]  D. Javitt,et al.  Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia , 2004, Biological Psychiatry.

[45]  M. Rogawski,et al.  Allopregnanolone Analogs That Positively Modulate GABAA Receptors Protect against Partial Seizures Induced by 6‐Hz Electrical Stimulation in Mice , 2004, Epilepsia.

[46]  J. Armijo,et al.  Association Between Patient Age and Gabapentin Serum Concentration-to-Dose Ratio: A Preliminary Multivariate Analysis , 2004, Therapeutic drug monitoring.

[47]  E. Perucca,et al.  A Comparative Study of the Effect of Carbamazepine and Valproic Acid on the Pharmacokinetics and Metabolic Profile of Topiramate at Steady State in Patients with Epilepsy , 2005, Epilepsia.

[48]  R. Reed,et al.  A Multiphasic Absorption Model Best Characterizes Gastrointestinal Absorption of Divalproex Sodium Extended‐Release Tablets , 2006, Journal of clinical pharmacology.

[49]  C. D. Thompson,et al.  Synthesis and in vitro reactivity of 3-carbamoyl-2-phenylpropionaldehyde and 2-phenylpropenal: putative reactive metabolites of felbamate. , 1996, Chemical research in toxicology.

[50]  N. Fejerman,et al.  A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy 1 This work was carried out on behalf of the International Pediatric Oxcarbazepine/Phenytoin Trial Group (Appendix A). 1 , 1997, Epilepsy Research.

[51]  The use of Monte Carlo simulations to study the effect of poor compliance on the steady state concentrations of valproic acid following administration of enteric‐coated and extended release divalproex sodium formulations , 2005, Biopharmaceutics & drug disposition.

[52]  S. Sisodiya,et al.  Widespread Upregulation of Drug‐resistance Proteins in Fatal Human Status Epilepticus , 2003, Epilepsia.

[53]  M. Bialer,et al.  Pharmacokinetic Analysis and Antiepileptic Activity of N-Valproyl Derivatives of GABA and Glycine , 1995, Pharmaceutical Research.

[54]  J. Rho,et al.  Epilepsy : scientific foundations of clinical practice , 2004 .

[55]  T. Kosten,et al.  Effects of topiramate in combination with intravenous nicotine in overnight abstinent smokers , 2005, Psychopharmacology.

[56]  C. Wasterlain,et al.  Brivaracetam Is A Potent Anticonvulsant In Experimental Status Epilepticus: 2.381 , 2005 .

[57]  M. Bialer.  New antiepileptic drugs that are second generation to existing antiepileptic drugs , 2006, Expert opinion on investigational drugs.

[58]  R. B. Carter,et al.  Characterization of the anticonvulsant properties of Ganaxolone (CCD 1042; 3α-hydroxy-3β-methyl-5α-pregnan-20-one), a selective, high-affinity, steroid modulator of the γ-aminobutyric acid(A) receptor , 1997 .

[59]  T Eke,et al.  Retrospective study of concussive convulsions in elite Australian rules and rugby league footballers: phenomenology, aetiology, and outcome , 1997, BMJ.

[60]  W. Löscher,et al.  D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures , 1996, Epilepsy Research.

[61]  O. Dulac,et al.  Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial , 2000, The Lancet.

[62]  K. Nocka,et al.  The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[63]  K. Petersen,et al.  A single dose of gabapentin reduces acute pain and allodynia in patients with herpes zoster , 2005, Neurology.

[64]  I. Sorri,et al.  Color vision and contrast sensitivity in epilepsy patients treated with initial tiagabine monotherapy , 2005, Epilepsy Research.

[65]  E. Mervaala,et al.  Long-term effects of tiagabine monotherapy on cognition and mood in adult patients with chronic partial epilepsy , 2006, Epilepsy & Behavior.

[66]  J. Davidson,et al.  Pregabalin in generalized anxiety disorder: a placebo-controlled trial. , 2003, The American journal of psychiatry.

[67]  Predicted plasma valproic acid concentrations in patients missing and replacing a full daily dose of extended-release divalproex sodium. , 2006, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[68]  G. Granneman,et al.  Every-12-hour administration of extended-release divalproex in patients with epilepsy: Impact on plasma valproic acid concentrations , 2006, Epilepsy & Behavior.

[69]  R. Reed,et al.  What Is the Best Strategy for Converting from Twice-Daily Divalproex to a Once-Daily Divalproex ER Regimen? , 2004, Clinical drug investigation.

[70]  D. Leys,et al.  Secondary prevention after ischemic stroke , 2005, Journal of Neurology.

[71]  C. Elger,et al.  What is the evidence that oxcarbazepine and carbamazepine are distinctly different antiepileptic drugs? , 2004, Epilepsy & Behavior.

[72]  B. Oken,et al.  Effects of topiramate and gabapentin on cognitive abilities in healthy volunteers , 2005, Neurology.

[73]  R. Robinson,et al.  Treatment of interictal epileptiform discharges can improve behavior in children with behavioral problems and epilepsy. , 2005, The Journal of pediatrics.

[74]  E. Perucca,et al.  Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI) , 2002, Epilepsy Research.

[75]  P. Crawford.  Best Practice Guidelines for the Management of Women with Epilepsy , 2005, Epilepsia.

[76]  P. Keck,et al.  Topiramate in the long-term treatment of binge-eating disorder associated with obesity. , 2004, Journal of Clinical Psychiatry.

[77]  R. Reed,et al.  Comparative Absorption Profiles of Divalproex Sodium Delayed-Release Versus Extended-Release Tablets—Clinical Implications , 2006, The Annals of pharmacotherapy.

[78]  T. May,et al.  Clinical Pharmacokinetics of Oxcarbazepine , 2003, Clinical pharmacokinetics.

[79]  M. Wang,et al.  Pharmacokinetics of tablet huperzine A in six volunteers. , 1995, Zhongguo yao li xue bao = Acta pharmacologica Sinica.

[80]  Conversion from delayed-release sodium valproate to extended-release sodium valproate: Initial results and long-term follow-up , 2006, Epilepsy & Behavior.

[81]  C. Westall,et al.  Longitudinal changes in photopic OPs occurring with vigabatrin treatment , 2003, Documenta Ophthalmologica.

[82]  J. Potter,et al.  Carbamazepine-10,11-epoxide in therapeutic drug monitoring. , 1998, Therapeutic drug monitoring.

[83]  T. Lerman-Sagie,et al.  Adverse reactions of Topiramate and Lamotrigine in children , 2005, Pharmacoepidemiology and drug safety.

[84]  Dieter Schmidt,et al.  Experimental and Clinical Evidence for Loss of Effect (Tolerance) during Prolonged Treatment with Antiepileptic Drugs , 2006, Epilepsia.

[85]  H. Diener,et al.  Topiramate Reduces Headache Days in Chronic Migraine: A Randomized, Double-Blind, Placebo-Controlled Study , 2007, Cephalalgia : an international journal of headache.

[86]  O. Dulac,et al.  Stiripentol: Efficacy and Tolerability in Children with Epilepsy , 1999, Epilepsia.

[87]  M. Bialer,et al.  Anticonvulsant Profile of Valrocemide (TV1901): A New Antiepileptic Drug , 2001, Epilepsia.

[88]  J. Tiihonen,et al.  Topiramate add-on in treatment-resistant schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial. , 2005, The Journal of clinical psychiatry.

[89]  D. Labar,et al.  Vagus nerve stimulation for 1 year in 269 patients on unchanged antiepileptic drugs , 2004, Seizure.

[90]  A. Krystal,et al.  Tiagabine increases slow-wave sleep in a dose-dependent fashion without affecting traditional efficacy measures in adults with primary insomnia. , 2006, Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine.

[91]  D. Goldstein,et al.  Common variation in the SCN1A gene is a risk factor for common forms of epilepsy associated with febrile seizures , 2004 .

[92]  P. Soares-da-Silva,et al.  Safety, Tolerability, and Pharmacokinetic Profile of BIA 2‐093, a Novel Putative Antiepileptic, in a Rising Multiple‐Dose Study in Young Healthy Humans , 2004, Journal of clinical pharmacology.

[93]  A. Zangara.  The psychopharmacology of huperzine A: an alkaloid with cognitive enhancing and neuroprotective properties of interest in the treatment of Alzheimer's disease , 2003, Pharmacology Biochemistry and Behavior.

[94]  D. Keating,et al.  Assessing Retinal Toxicity of Vigabatrin and Other Gaga–Ergic Drugs in Patients With Epilepsy , 2006 .

[95]  Michael L.J. Apuzzo,et al.  Vagus nerve stimulation therapy after failed cranial surgery for intractable epilepsy: results from the vagus nerve stimulation therapy patient outcome registry. , 2004, Neurosurgery.

[96]  R. Reed,et al.  Does It Really Matter When a Blood Sample for Valproic Acid Concentration is Taken Following Once-Daily Administration of Divalproex-ER? , 2006, Therapeutic drug monitoring.

[97]  C. Bucca,et al.  Effects of Levetiracetam on Nocturnal Sleep and Daytime Vigilance in Healthy Volunteers , 2006, Epilepsia.

[98]  E. Ongini,et al.  A nitric oxide (NO)‐releasing derivative of gabapentin, NCX 8001, alleviates neuropathic pain‐like behavior after spinal cord and peripheral nerve injury , 2004, British journal of pharmacology.

[99]  M. Bialer,et al.  Pharmacokinetic Interaction Study between the New Antiepileptic and CNS Drug RWJ‐333369 and Carbamazepine in Healthy Adults , 2006, Epilepsia.

[100]  P. Crawford.  Interactions Between Antiepileptic Drugs and Hormonal Contraception , 2002, CNS drugs.

[101]  Mike R. Schoenberg,et al.  Subjective preference for lamotrigine or topiramate in healthy volunteers: Relationship to cognitive and behavioral functioning , 2006, Epilepsy & Behavior.

[102]  C. Fontes-Ribeiro,et al.  Eslicarbazepine Acetate (BIA 2-093) , 2005 .

[103]  M. Carotenuto,et al.  Lamotrigine as first-line drug in childhood absence epilepsy: a clinical and neurophysiological study , 2004, Brain and Development.

[104]  S. Dutta,et al.  Comparison of the bioavailability of unequal doses of divalproex sodium extended-release formulation relative to the delayed-release formulation in healthy volunteers , 2002, Epilepsy Research.

[105]  G Bernardi,et al.  Lamotrigine inhibits Ca2+ currents in cortical neurons: functional implications. , 1996, European journal of pharmacology.

[106]  J. Treluyer,et al.  Inhibitory effect of stiripentol on carbamazepine and saquinavir metabolism in human. , 2003, British journal of clinical pharmacology.

[107]  H. Zhang,et al.  Huperzine A attenuates cognitive deficits and hippocampal neuronal damage after transient global ischemia in gerbils , 2001, Neuroscience Letters.

[108]  D. Bennett,et al.  Oxcarbazepine adjunctive therapy in infants and young children with partial seizures , 2005, Neurology.

[109]  B. Uthman,et al.  New onset geriatric epilepsy , 2005, Neurology.

[110]  E. Monaghan,et al.  Initial Human Experience with Ganaxolone, a Neuroactive Steroid with Antiepileptic Activity , 1997, Epilepsia.

[111]  S. Ramael,et al.  Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects. , 2006, Clinical therapeutics.

[112]  J. Calabrese,et al.  Newer treatment studies for bipolar depression. , 2005, Bipolar disorders.

[113]  J. Cramer,et al.  The relationship between poor medication compliance and seizures , 2002, Epilepsy & Behavior.

[114]  S. Shapiro,et al.  Evaluation of Case Reports of Aplastic Anemia Among Patients Treated with Felbamate , 1997, Epilepsia.

[115]  B. Uthman,et al.  Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy , 2005, Neurology.

[116]  Jeffrey S. Brown,et al.  Cost‐Effectiveness of Topiramate in Migraine Prevention: Results From a Pharmacoeconomic Model of Topiramate Treatment , 2005, Headache.

[117]  A. Rush,et al.  Lamotrigine for bipolar disorder and comorbid cocaine dependence: a replication and extension study. , 2006, Journal of affective disorders.

[118]  M. Remler,et al.  Felbamate monotherapy for partial‐onset seizures , 1993, Neurology.

[119]  B. Uthman,et al.  Bioavailability of a Divalproex Extended-Release Formulation versus the Conventional Divalproex Formulation in Adult Patients Receiving Enzyme-Inducing Antiepileptic Drugs , 2003, Clinical drug investigation.

[120]  E. Perucca.  Drugs Under Clinical Trial , 1999 .

[121]  R. Reed,et al.  Divalproex to Divalproex Extended Release Conversion , 2004, Clinical drug investigation.

[122]  A. Fink-Jensen,et al.  The gamma-aminobutyric acid (GABA) uptake inhibitor, tiagabine, increases extracellular brain levels of GABA in awake rats. , 1992, European journal of pharmacology.

[123]  Michael A. Rogawski,et al.  Diverse mechanisms of antiepileptic drugs in the development pipeline , 2006, Epilepsy Research.

[124]  M. Bialer,et al.  Pharmacokinetics of the New Antiepileptic and CNS Drug RWJ‐333369 Following Single and Multiple Dosing to Humans , 2006, Epilepsia.

[125]  A. Nehlig,et al.  Long‐term Pregabalin Treatment Protects Basal Cortices and Delays the Occurrence of Spontaneous Seizures in the Lithium‐Pilocarpine Model in the Rat , 2003, Epilepsia.

[126]  R. Poole,et al.  Pregabalin for the treatment of postherpetic neuralgia , 2003, Neurology.

[127]  E. Perucca,et al.  Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (EILAT IV) , 1999, Epilepsy Research.

[128]  F. Drislane,et al.  Differential effects of antiepileptic drugs on sexual function and hormones in men with epilepsy , 2005, Neurology.

[129]  O. Dulac,et al.  Effect of stiripentol on carbamazepine plasma concentration and metabolism in epileptic children , 1996, European Journal of Clinical Pharmacology.

[130]  J. Dave,et al.  Huperzine A, a potential therapeutic agent for dementia, reduces neuronal cell death caused by glutamate , 1997, Neuroreport.

[131]  G. Blackburn-Munro,et al.  Behavioural effects of the novel AMPA/GluR5 selective receptor antagonist NS1209 after systemic administration in animal models of experimental pain , 2004, Neuropharmacology.

[132]  O. Henriksen,et al.  Rufinamide: a double-blind, placebo-controlled proof of principle trial in patients with epilepsy , 2001, Epilepsy Research.

[133]  E. Nielsen,et al.  In Vitro Characterization of 5-Carboxyl-2,4-di-benzamidobenzoic Acid (NS3763), a Noncompetitive Antagonist of GLUK5 Receptors , 2004, Journal of Pharmacology and Experimental Therapeutics.

[134]  M. J. Field,et al.  Pregabalin may represent a novel class of anxiolytic agents with a broad spectrum of activity , 2001, British journal of pharmacology.

[135]  C. Mathiesen,et al.  SPD 502: a water-soluble and in vivo long-lasting AMPA antagonist with neuroprotective activity. , 1999, The Journal of pharmacology and experimental therapeutics.

[136]  Anthony L. Johnson,et al.  The United Kingdom Infantile Spasms Study comparing vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre, randomised controlled trial , 2004, The Lancet.

[137]  T. Schwartz,et al.  An open-label study of tiagabine as augmentation therapy for anxiety. , 2005, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

[138]  J. Boggs,et al.  Successful Initiation of Combined Therapy with Valproate Sodium Injection and Divalproex Sodium Extended‐release Tablets in the Epilepsy Monitoring Unit , 2005, Epilepsia.

[139]  H. Clusmann,et al.  Inhibition of neuronal Ca2+ influx by gabapentin and pregabalin in the human neocortex , 2002, Neuropharmacology.

[140]  A. McKnight,et al.  Gabapentin inhibits the substance P-facilitated K+-evoked release of [3H]glutamate from rat caudal trigeminal nucleus slices , 2001, Pain.

[141]  E. Brodtkorb,et al.  Ethinyl Estradiol, Not Progestogens, Reduces Lamotrigine Serum Concentrations , 2005, Epilepsia.

[142]  M. Brodie,et al.  Pregabalin Drug Interaction Studies: Lack of Effect on the Pharmacokinetics of Carbamazepine, Phenytoin, Lamotrigine, and Valproate in Patients with Partial Epilepsy , 2005, Epilepsia.

[143]  M. Vergnes,et al.  Activity profile of pregabalin in rodent models of epilepsy and ataxia , 2006, Epilepsy Research.

[144]  J. Barbet,et al.  Protective effect of stiripentol on acetaminophen-induced hepatotoxicity in rat. , 2001, Toxicology and applied pharmacology.

[145]  E. Perucca,et al.  Changes in the Disposition of Oxcarbazepine and Its Metabolites during Pregnancy and the Puerperium , 2006, Epilepsia.

[146]  K. Laxer,et al.  Assessment of Ganaxolone's Anticonvulsant Activity Using a Randomized, Double‐Blind, Presurgical Trial Design , 2000, Epilepsia.

[147]  C. Taylor.  The Biology and Pharmacology of Calcium Channel α2-δ Proteins Pfizer satellite symposium to the 2003 Society for Neuroscience Meeting Sheraton New Orleans Hotel New Orleans, LA November 10, 2003 , 2006 .

[148]  Brian D. Hale,et al.  Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A). , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[149]  Robert S. Pinals,et al.  A double‐blind, placebo‐controlled trial , 1986 .

[150]  T. Tomson,et al.  Effects of the antiepileptic drugs lamotrigine, topiramate and gabapentin on hERG potassium currents , 2005, Epilepsy Research.

[151]  S. Dutta,et al.  Bioavailability of divalproex extended‐release formulation relative to the divalproex delayed‐release formulation , 2004, Biopharmaceutics & drug disposition.

[152]  M. Rogawski,et al.  Anticonvulsant activity of AMPA/kainate antagonists: comparison of GYKI 52466 and NBQX in maximal electroshock and chemoconvulsant seizure models , 1993, Epilepsy Research.

[153]  E. Perucca,et al.  Plasma Gabapentin Concentrations in Children With Epilepsy: Influence of Age, Relationship With Dosage, and Preliminary Observations on Correlation With Clinical Response , 2003, Therapeutic drug monitoring.

[154]  C. Wasterlain,et al.  N-methyl-d-asparate receptor antagonists abolish the maintenance phase of self-sustaining status epilepticus in rat , 1999, Neuroscience Letters.

[155]  M. Vasko,et al.  Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C , 2003, Pain.

[156]  C Barber,et al.  Electro‐Oculography, Electroretinography, Visual Evoked Potentials, and Multifocal Electroretinography in Patients with Vigabatrin‐Attributed Visual Field Constriction , 2000, Epilepsia.

[157]  B. Wlodarczyk,et al.  Effect of stiripentol dose on phenytoin-induced teratogenesis in a mouse model. , 1999, Reproductive toxicology.

[158]  J. Boggs.  Elderly Patients with Systemic Disease , 2001, Epilepsia.

[159]  A. Aldenkamp,et al.  The Effect of the New Antiepileptic Drug Rufinamide on Cognitive Functions , 2006, Epilepsia.

[160]  M. Gillard,et al.  Discovery of 4-substituted pyrrolidone butanamides as new agents with significant antiepileptic activity. , 2004, Journal of medicinal chemistry.

[161]  R. Barrett,et al.  XP13512 [(±)-1-([(α-Isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane Acetic Acid], A Novel Gabapentin Prodrug: I. Design, Synthesis, Enzymatic Conversion to Gabapentin, and Transport by Intestinal Solute Transporters , 2004, Journal of Pharmacology and Experimental Therapeutics.

[162]  R. Wenzel,et al.  Topiramate for Migraine Prevention , 2006, Pharmacotherapy.

[163]  H. Ohtsu,et al.  Development of Amygdaloid Kindling in Histidine Decarboxylase–deficient and Histamine H1 Receptor–deficient Mice , 2004, Epilepsia.

[164]  A. Marson,et al.  The New Antiepileptic Drugs: A Systematic Review of Their Efficacy and Tolerability , 1997, BMJ.

[165]  J. Osborne,et al.  The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial , 2005, The Lancet Neurology.

[166]  M. Rogawski,et al.  GYKI 52466, a 2,3-benzodiazepine, is a highly selective, noncompetitive antagonist of AMPA/kainate receptor responses , 1993, Neuron.

[167]  E. Mervaala,et al.  Comparison of the Cognitive Effects of Tiagabine and Carbamazepine as Monotherapy in Newly Diagnosed Adult Patients with Partial Epilepsy: Pooled Analysis of Two Long‐term, Randomized, Follow‐up Studies , 2006, Epilepsia.

[168]  M. Bialer,et al.  The Absorption, Metabolism, and Excretion of the Novel Neuromodulator RWJ-333369 (1,2-Ethanediol, [1-2-Chlorophenyl]-, 2-carbamate, [S]-) in Humans , 2007, Drug Metabolism and Disposition.

[169]  Michael C. Smith,et al.  Clinical comparison of extended-release divalproex versus delayed-release divalproex: pooled data analyses from nine trials , 2004, Epilepsy & Behavior.

[170]  I. Rosén,et al.  Vagus nerve stimulation in 15 children with therapy resistant epilepsy; its impact on cognition, quality of life, behaviour and mood , 2005, Seizure.

[171]  Peter K. Leiberich,et al.  Topiramate treatment in bulimia nervosa patients: a randomized, double-blind, placebo-controlled trial. , 2005, The International journal of eating disorders.

[172]  D. Margineanu,et al.  Inhibition of neuronal hypersynchrony in vitro differentiates levetiracetam from classical antiepileptic drugs. , 2000, Pharmacological research.

[173]  J. Sackellares,et al.  Double-blind, placebo-controlled study of lamotrigine in primary generalized tonic-clonic seizures , 2005, Neurology.

[174]  H. Nau,et al.  Enantioselective synthesis and teratogenicity of propylisopropyl acetamide, a CNS-active chiral amide analogue of valproic acid. , 1999, Chirality.

[175]  S. Dutta,et al.  Effect of delayed and/or missed enteric‐coated divalproex doses on valproic acid concentrations: simulation and dose replacement recommendations for the clinician 1 , 2006, Journal of clinical pharmacy and therapeutics.

[176]  A. Patat,et al.  Lack of pharmacokinetic interaction between retigabine and phenobarbitone at steady-state in healthy subjects. , 2003, British journal of clinical pharmacology.

[177]  T. Roth,et al.  Effect of tiagabine on sleep in elderly subjects with primary insomnia: a randomized, double-blind, placebo-controlled study. , 2006, Sleep.

[178]  K. Yaffe,et al.  Prognostic factors of pentobarbital therapy for refractory generalized status epilepticus , 1993, Neurology.

[179]  R. Lipton,et al.  Efficacy and Safety of Topiramate for the Treatment of Chronic Migraine: A Randomized, Double‐Blind, Placebo‐Controlled Trial , 2007, Headache.

[180]  B. Uludaǧ,et al.  Effects of lamotrigine on the symptoms and life qualities of patients with post polio syndrome: a randomized, controlled study. , 2005, NeuroRehabilitation.

[181]  G. Bennett,et al.  Stereoselective Pharmacokinetics and Pharmacodynamics of Propylisopropyl Acetamide, a CNS-Active Chiral Amide Analog of Valproic Acid , 1999, Pharmaceutical Research.

[182]  M. Javors,et al.  Use of oral topiramate to promote smoking abstinence among alcohol-dependent smokers: a randomized controlled trial. , 2005, Archives of internal medicine.

[183]  M. Pollack,et al.  The selective GABA reuptake inhibitor tiagabine for the treatment of generalized anxiety disorder: results of a placebo-controlled study. , 2005, The Journal of clinical psychiatry.

[184]  A. Marson,et al.  Lamotrigine versus carbamazepine monotherapy for epilepsy. , 2006, The Cochrane database of systematic reviews.

[185]  H. Baik,et al.  Topiramate stimulates glucose transport through AMP-activated protein kinase-mediated pathway in L6 skeletal muscle cells , 2006, The Pharmacogenomics Journal.

[186]  M. Bialer.  Clinical Pharmacology of Valpromide , 1991, Clinical pharmacokinetics.

[187]  Mike R. Schoenberg,et al.  Cognitive and behavioral effects of lamotrigine and topiramate in healthy volunteers , 2005, Neurology.

[188]  Wang-Tso Lee,et al.  Hemophagocytic syndrome associated with antiepileptic drug. , 2004, Pediatric neurology.

[189]  P. Rutecki,et al.  Determinants of Ictal Epileptiform Patterns in the Hippocampal Slice , 2002, Epilepsia.

[190]  S. Whetzel,et al.  Preferential action of gabapentin and pregabalin at P/Q‐type voltage‐sensitive calcium channels: Inhibition of K+‐evoked [3H]‐norepinephrine release from rat neocortical slices , 2002, Synapse.

[191]  T. Roth,et al.  Tiagabine enhances slow wave sleep and sleep maintenance in primary insomnia. , 2006, Sleep medicine.

[192]  K. Chang,et al.  An open-label study of lamotrigine adjunct or monotherapy for the treatment of adolescents with bipolar depression. , 2006, Journal of the American Academy of Child and Adolescent Psychiatry.

[193]  P. Neuvonen,et al.  Concentrations and Effects of Oral Midazolam are Greatly Reduced in Patients Treated with Carbamazepine or Phenytoin , 1996, Epilepsia.

[194]  F. Huguet,et al.  A new type of anticonvulsant, stiripentol. Pharmacological profile and neurochemical study. , 1984, Arzneimittel-Forschung.

[195]  D J Rowbotham,et al.  Gabapentin: a new drug for postoperative pain? , 2006, British journal of anaesthesia.

[196]  M. Bialer,et al.  Plasma and whole blood pharmacokinetics of topiramate: the role of carbonic anhydrase , 2005, Epilepsy Research.

[197]  Peter K. Leiberich,et al.  Topiramate in Treatment of Patients With Chronic Low Back Pain: A Randomized, Double-blind, Placebo-controlled Study , 2006, The Clinical journal of pain.

[198]  S. Arroyo,et al.  Pregabalin Add‐on Treatment: A Randomized, Double‐blind, Placebo‐controlled, Dose–Response Study in Adults with Partial Seizures , 2004, Epilepsia.

[199]  J. Davidson,et al.  Tiagabine for posttraumatic stress disorder: effects of open-label and double-blind discontinuation treatment , 2005, Psychopharmacology.

[200]  E. Giacobini,et al.  Second generation cholinesterase inhibitors: Effect of (L)‐huperzine‐A on cortical biogenic amines , 1995, Journal of neuroscience research.

[201]  J. Cai,et al.  Improving effects of huperzine A on spatial working memory in aged monkeys and young adult monkeys with experimental cognitive impairment. , 1999, The Journal of pharmacology and experimental therapeutics.

[202]  M. Yoshita,et al.  MRI of segmental zoster paresis , 2005, Neurology.

[203]  R. Netzer,et al.  The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells tranfected with human KCNQ2/3 subunits , 2000, Neuroscience Letters.

[204]  R. Jakus,et al.  Effect of two noncompetitive AMPA receptor antagonists GYKI 52466 and GYKI 53405 on vigilance, behavior and spike–wave discharges in a genetic rat model of absence epilepsy , 2004, Brain Research.

[205]  Paul Rutecki,et al.  Inter- and intra-subject variability in gabapentin absorption and absolute bioavailability , 2000, Epilepsy Research.

[206]  A. Falcão,et al.  Single‐Dose and Steady‐State Pharmacokinetics of Eslicarbazepine Acetate (BIA 2–093) in Healthy Elderly and Young Subjects , 2005, Journal of clinical pharmacology.

[207]  R. Cunha,et al.  Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives. , 1999, Journal of medicinal chemistry.

[208]  R. Pohl,et al.  Pregabalin: a new anxiolytic , 2003, Expert opinion on investigational drugs.

[209]  B. Irwin,et al.  Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[210]  C. Elger,et al.  Pregabalin Add‐on Treatment in Patients with Partial Seizures: A Novel Evaluation of Flexible‐dose and Fixed‐dose Treatment in a Double‐blind, Placebo‐controlled Study , 2005, Epilepsia.

[211]  J. Borlak,et al.  Pharmacokinetic interaction between retigabine and lamotrigine in healthy subjects , 2003, European Journal of Clinical Pharmacology.

[212]  P. Loiseau,et al.  Stiripentol kinetics in epilepsy: Nonlinearity and interactions , 1984, Clinical pharmacology and therapeutics.

[213]  M. Bialer,et al.  Structure‐Pharmacokinetic‐Pharmacodynamic Relationships of yV‐Alkyl Derivatives of the New Antiepileptic Drug Valproyl Glycinamide , 1999, Epilepsia.

[214]  R. Sankar,et al.  Treatment of Experimental Status Epilepticus in Immature Rats: Dissociation Between Anticonvulsant and Antiepileptogenic Effects , 2006, Pediatric Research.

[215]  M. Moskowitz,et al.  Suppression of cortical spreading depression in migraine prophylaxis , 2006, Annals of neurology.

[216]  G. Hu,et al.  Spermidine antagonizes the inhibitory effect of huperzine A on [3H]dizocilpine (MK-801) binding in synaptic membrane of rat cerebral cortex , 2002, Neuroscience Letters.

[217]  E. Ben-Menachem,et al.  Topiramate reduces AMPA‐induced Ca2+ transients and inhibits GluR1 subunit phosphorylation in astrocytes from primary cultures , 2005, Journal of neurochemistry.

[218]  D. Bloch,et al.  A placebo-controlled screening trial of tiagabine, sertraline and donepezil as cocaine dependence treatments. , 2005, Addiction.

[219]  R. Kälviäinen,et al.  Visual Field Defects with Vigabatrin , 2001, CNS drugs.

[220]  R. Reed,et al.  Absolute Bioavailability and Absorption Characteristics of Divalproex Sodium Extended‐Release Tablets in Healthy Volunteers , 2004, Journal of clinical pharmacology.

[221]  F. López-Muñoz,et al.  Effects of lamotrigine in patients with bipolar disorder and alcohol dependence. , 2006, Bipolar disorders.

[222]  S. Ramael,et al.  Levetiracetam Intravenous Infusion: A Randomized, Placebo‐controlled Safety and Pharmacokinetic Study , 2006, Epilepsia.

[223]  T. Liljefors,et al.  The structure of a mixed GluR2 ligand-binding core dimer in complex with (S)-glutamate and the antagonist (S)-NS1209. , 2006, Journal of molecular biology.

[224]  C. D. Thompson,et al.  Potentially reactive cyclic carbamate metabolite of the antiepileptic drug felbamate produced by human liver tissue in vitro. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[225]  B. Uthman,et al.  Extended-release formulations: simplifying strategies in the management of antiepileptic drug therapy , 2004, Epilepsy & Behavior.

[226]  René H Levy,et al.  Pharmacokinetic and Metabolic Investigation of Topiramate Disposition in Healthy Subjects in the Absence and in the Presence of Enzyme Induction by Carbamazepine , 2005, Epilepsia.

[227]  G. Harding,et al.  Field-specific visual-evoked potentials: Identifying field defects in vigabatrin-treated children , 2002, Neurology.

[228]  Raquel G Dos Santos,et al.  The novel GABA adamantane derivative (AdGABA): design, synthesis, and activity relationship with gabapentin. , 2005, Bioorganic & medicinal chemistry.

[229]  C. Elger,et al.  The Mechanism of Neuroprotection by Topiramate in an Animal Model of Epilepsy , 2004, Epilepsia.

[230]  C. Wasterlain,et al.  Anticonvulsant and antiepileptogenic effects of fluorofelbamate in experimental status epilepticus , 2002, Seizure.

[231]  J. Sidhu,et al.  The pharmacokinetic and pharmacodynamic consequences of the co-administration of lamotrigine and a combined oral contraceptive in healthy female subjects. , 2006, British journal of clinical pharmacology.

[232]  F. Menniti,et al.  Molecular Mechanism of AMPA Receptor Noncompetitive Antagonism , 2005, Neuron.

[233]  T. Tomson,et al.  Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII) , 2004, Epilepsy Research.

[234]  H. Myrick,et al.  A Retrospective Chart Review Comparing Tiagabine and Benzodiazepines for the Treatment of Alcohol Withdrawal , 2005, Journal of psychoactive drugs.

[235]  L. Price,et al.  Open-label tiagabine monotherapy for major depressive disorder with anxiety. , 2006, The Journal of clinical psychiatry.

[236]  A. Sedman,et al.  Pharmacokinetics of Pregabalin in Subjects with Various Degrees of Renal Function , 2003, Journal of clinical pharmacology.

[237]  Ping Jiang,et al.  Extended‐release Divalproex in Child and Adolescent Outpatients with Epilepsy , 2005, Epilepsia.

[238]  J. Sackellares,et al.  Felbamate , 1993, Neurology.

[239]  E. Bachler,et al.  Topiramate Treatment for Women With Borderline Personality Disorder: A Double-blind, Placebo-Controlled Study , 2006, Journal of clinical psychopharmacology.

[240]  C. Dahlöf,et al.  Topiramate Improves Health‐Related Quality of Life When Used to Prevent Migraine , 2005, Headache.

[241]  R. Beran,et al.  The absorption of gabapentin following high dose escalation , 2003, Seizure.

[242]  G. Morris,et al.  Vagus nerve stimulation therapy: 5-year or greater outcome at a university-based epilepsy center , 2004, Seizure.

[243]  O. Devinsky,et al.  Vagus nerve stimulation for refractory idiopathic generalised epilepsy , 2004, Seizure.

[244]  M. Rogawski,et al.  Chronic treatment with the neuroactive steroid ganaxolone in the rat induces anticonvulsant tolerance to diazepam but not to itself. , 2000, The Journal of pharmacology and experimental therapeutics.

[245]  J. Hulihan,et al.  Topiramate for Migraine Prevention in Children: A Randomized, Double‐Blind, Placebo‐Controlled Trial , 2005, Headache.